ClinicalTrials.Veeva

Menu

Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure (GLUCOSUR-IC)

G

Germans Trias i Pujol Hospital

Status

Completed

Conditions

Heart Failure

Treatments

Drug: iSGTL2

Study type

Observational

Funder types

Other

Identifiers

NCT03741972
ICO-2018-03-PA-Glucosur

Details and patient eligibility

About

Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and hemodynamic profile in patients with DM2 and heart failure.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Type 2 Diabetes
  • HbA1c> 6.5%
  • Estimated GF> 45 ml / min
  • BMI: ≥25 Kg / m2
  • Stable pharmacological treatment of Heart Failure in the last 3 months

Exclusion criteria

  • Diabetes type 1 or type LADA (presence of antibodies against GAD and/or IA-2 positive)
  • DM2 with C-peptide <1 ng / mL
  • GEF <45 ml / min
  • Recurrent urinary tract infections

Trial design

100 participants in 1 patient group

Treatment
Description:
Patients with diabetes and heart failure that are treated with iSGLT2
Treatment:
Drug: iSGTL2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems